Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

References

• LevineRLGillilandDGMyeloproliferative disordersBlood200811262190219818779404
   PubMed Web of Science ®Google Scholar
• GregorySAMesaRAHoffmanRShammoJMClinical and laboratory features of myelofibrosis and limitations of current therapiesClin Adv Hematol Oncol201199 Suppl 2211622362131
   PubMedGoogle Scholar
• CervantesFDupriezBPereiraANew prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood2009113132895290118988864
   PubMed Web of Science ®Google Scholar
• PassamontiFCervantesFVannucchiAMDynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosisBlood2010116152857285820947690
   PubMed Web of Science ®Google Scholar
• MehtaJWangHIqbalSUMesaREpidemiology of myeloproliferative neoplasms in the United StatesLeuk Lymphoma Epub7292013
   Web of Science ®Google Scholar
• AksoyMMalignancies due to occupational exposure to benzeneHaematologica19806533703736778789
   PubMed Web of Science ®Google Scholar
• TondelMPerssonBCarstensenJMyelofibrosis and benzene exposureOccup Med (Lond)199545151527703476
   PubMed Web of Science ®Google Scholar
• BoschXCampistolJMMontoliuJRevertLMyelofibrosis and focal segmental glomerulosclerosis associated with toluene poisoningHum Toxicol1988743573613410485
   PubMedGoogle Scholar
• MesaRAGreenABarosiGVerstovsekSVardimanJGaleRPMPN-associated myelofibrosis (MPN-MF)Leuk Res2011351121320684988
   PubMed Web of Science ®Google Scholar
• Jakafi® (Ruxolitinib) tablets, for oral use [prescribing information]Wilmington, DEIncyte Corporation Available from: http://www.incyte.com/products/uspi_jakafi.pdfAccessed September 9, 2013
   Google Scholar
• VerstovsekSMesaRAGotlibJA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisN Engl J Med2012366979980722375971
   PubMed Web of Science ®Google Scholar
• HarrisonCKiladjianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for myelofibrosisN Engl J Med2012366978779822375970
   PubMed Web of Science ®Google Scholar
• VerstovsekSKantarjianHMesaRASafety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisN Engl J Med2010363121117112720843246
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJEfficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-IHaematologica Epub2013913
   Web of Science ®Google Scholar
• CervantesFKiladjianJJNiederwieserDLong-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF)Blood (ASH Annual Meeting Abstracts)201212021 Abstract 801
   Google Scholar
• VardimanJWThieleJArberDAThe 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood2009114593795119357394
   PubMed Web of Science ®Google Scholar
• LatailladeJJPierre-LouisOHasselbalchHCFrench INSERM and the European EUMNET Networks on MyelofibrosisDoes primary myelofibrosis involve a defective stem cell niche? From concept to evidenceBlood200811283026303518669872
   PubMed Web of Science ®Google Scholar
• PrchalJFAxelradAABone marrow responses in polycythemia veraN Engl J Med19742902413824827655
   PubMed Web of Science ®Google Scholar
• AdamsonJWFialkowPJMurphySPrchalJFSteinmannLPolycythemia vera: stem-cell and probable clonal origin of the diseaseN Engl J Med197629517913916967201
   PubMed Web of Science ®Google Scholar
• FialkowPJFaguetGBJacobsonRJVaidyaKMurphySEvidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cellBlood19815859169197296002
   PubMed Web of Science ®Google Scholar
• XuMBrunoEChaoJThe constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosisBlood200510541699170515471948
   PubMed Web of Science ®Google Scholar
• RöderSSteimleCMeinhardtGPahlHLSTAT3 is constitutively active in some patients with Polycythemia rubra veraExp Hematol200129669470211378264
   PubMed Web of Science ®Google Scholar
• UgoVMarzacCTeyssandierIMultiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia veraExp Hematol200432217918715102479
   PubMed Web of Science ®Google Scholar
• VainchenkerWDelhommeauFConstantinescuSNBernardOANew mutations and pathogenesis of myeloproliferative neoplasmsBlood201111871723173521653328
   PubMed Web of Science ®Google Scholar
• BaxterEJScottLMCampbellPJCancer Genome ProjectAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersLancet200536594641054106115781101
   PubMed Web of Science ®Google Scholar
• JamesCUgoVLe CouédicJPA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature200543470371144114815793561
   PubMed Web of Science ®Google Scholar
• KralovicsRPassamontiFBuserASA gain-of-function mutation of JAK2 in myeloproliferative disordersN Engl J Med2005352171779179015858187
   PubMed Web of Science ®Google Scholar
• LevineRLWadleighMCoolsJActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell20057438739715837627
   PubMed Web of Science ®Google Scholar
• CrossNCGenetic and epigenetic complexity in myeloproliferative neoplasmsHematology Am Soc Hematol Educ Program2011201120821422160036
   PubMed Web of Science ®Google Scholar
• OkuSTakenakaKKuriyamaTJAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activationBr J Haematol2010150333434420553273
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAKantarjianHCortesJVerstovsekSJanus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondNat Rev Drug Discov201110212714021283107
   PubMed Web of Science ®Google Scholar
• MesaRAVerstovsekSGuptaVImprovement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-IBlood (ASH Annual Meeting Abstracts)201212021 Abstract 1733
   Google Scholar
• TefferiANovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia20102461128113820428194
   PubMed Web of Science ®Google Scholar
• VainchenkerWConstantinescuSNJAK/STAT signaling in hematological malignanciesOncogene201332212601261322869151
   PubMed Web of Science ®Google Scholar
• TefferiAJimmaTSulaiNHIDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FLeukemia201226347548021912393
   PubMed Web of Science ®Google Scholar
• VannucchiAMBiamonteFEpigenetics and mutations in chronic myeloproliferative neoplasmsHaematologica201196101398140221972209
   PubMed Web of Science ®Google Scholar
• SchaubFXLooserRLiSClonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasmsBlood2010115102003200720061559
   PubMed Web of Science ®Google Scholar
• RumiEHarutyunyanAElenaCIdentification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasmAm J Hematol2011861297497921953568
   PubMed Web of Science ®Google Scholar
• HummelJMKleteckaMCSanksJKConcomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasmsDiagn Mol Pathol201221317618322847163
   PubMedGoogle Scholar
• PikmanYLeeBHMercherTMPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaPLoS Med200637e27016834459
   PubMed Web of Science ®Google Scholar
• ScottLMTongWLevineRLJAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisN Engl J Med2007356545946817267906
   PubMed Web of Science ®Google Scholar
• PassamontiFElenaCSchnittgerSMolecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsBlood2011117102813281621224469
   PubMed Web of Science ®Google Scholar
• Abdel-WahabOPardananiABernardOAUnraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumAm J Hematol201287556256822460584
   PubMed Web of Science ®Google Scholar
• WalzCAhmedWLazaridesKEssential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in miceBlood2012119153550356022234689
   PubMed Web of Science ®Google Scholar
• ConstantinescuSNVainchenkerWSmall-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Hematology Am Soc Hematol Educ Program2012201255356023233634
   PubMed Web of Science ®Google Scholar
• Le Bousse-KerdilèsMCMartyréMCSamsonMCellular and molecular mechanisms underlying bone marrow and liver fibrosis: a reviewEur Cytokine Netw2008192698018632420
   PubMed Web of Science ®Google Scholar
• TefferiAPathogenesis of myelofibrosis with myeloid metaplasiaJ Clin Oncol200523338520853016293880
   PubMed Web of Science ®Google Scholar
• KreipeHBüscheGBockOHusseinKMyelofibrosis: molecular and cell biological aspectsFibrogenesis Tissue Repair20125Suppl 1S2123259436
   PubMedGoogle Scholar
• Le Bousse-KerdilèsMCPrimary myelofibrosis and the “bad seeds in bad soil” conceptFibrogenesis Tissue Repair20125Suppl 1S2023259918
   PubMedGoogle Scholar
• PassamontiFRumiEPietraDA prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complicationsLeukemia20102491574157920631743
   PubMed Web of Science ®Google Scholar
• ThieleJKvasnickaHMFacchettiFFrancoVvan der WaltJOraziAEuropean consensus on grading bone marrow fibrosis and assessment of cellularityHaematologica20059081128113216079113
   PubMed Web of Science ®Google Scholar
• GianelliUVenerCBossiAThe European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosisMod Pathol20122591193120222627739
   PubMed Web of Science ®Google Scholar
• KrögerNKvasnickaMThieleJReplacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosisFibrogenesis Tissue Repair20125Suppl 1S2523259545
   PubMedGoogle Scholar
• GuptaVHariPHoffmanRAllogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitorsBlood201212071367137922700718
   PubMed Web of Science ®Google Scholar
• PatriarcaFBacigalupoASperottoAGITMOAllogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Haematologica200893101514152218728030
   PubMed Web of Science ®Google Scholar
• BallenKKShresthaSSobocinskiKAOutcome of transplantation for myelofibrosisBiol Blood Marrow Transplant201016335836719879949
   PubMed Web of Science ®Google Scholar
• ZangDYDeegHJAllogeneic hematopoietic cell transplantation for patients with myelofibrosisCurr Opin Hematol200916214014619468277
   PubMed Web of Science ®Google Scholar
• MesaRALiCYKetterlingRPSchroederGSKnudsonRATefferiALeukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 casesBlood2005105397397715388582
   PubMed Web of Science ®Google Scholar
• KundrandaMNTibesRMesaRATransformation of a chronic myelo-proliferative neoplasm to acute myelogenous leukemia: does anything work?Curr Hematol Malig Rep201271788622170483
   PubMed Web of Science ®Google Scholar
• TefferiALashoTLJimmaTOne thousand patients with primary myelofibrosis: the mayo clinic experienceMayo Clin Proc2012871253322212965
   PubMed Web of Science ®Google Scholar
• GangatNCaramazzaDVaidyaRDIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion statusJ Clin Oncol201129439239721149668
   PubMed Web of Science ®Google Scholar
• TefferiAPardananiAGangatNLeukemia risk models in primary myelofibrosis: an International Working Group studyLeukemia20122661439144122289985
   PubMed Web of Science ®Google Scholar
• Lopes da SilvaRRibeiroPLourençoAWhat is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?Lab Hematol2011171121621421540
   PubMedGoogle Scholar
• HelbigGWieczorkiewiczAWoŸniczkaKWiśniewska-PiatyKRusekAKyrcz-KrzemieńSThe JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosisMed Oncol20122942379238422383244
   PubMed Web of Science ®Google Scholar
• KreftASpringerELipkaDBKirkpatrickCJWild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosisActa Haematol20091221363819713696
   PubMed Web of Science ®Google Scholar
• WuYYHungHMChenTSChaoTYHoCLDecreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformationLeuk Res200832111783178618455791
   PubMed Web of Science ®Google Scholar
• TheocharidesABoissinotMGirodonFLeukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutationBlood2007110137537917363731
   PubMed Web of Science ®Google Scholar
• NielsenIHasselbalchHCAcute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphanAm J Hematol2003741263112949887
   PubMed Web of Science ®Google Scholar
• KiladjianJJChevretSDosquetCChomienneCRainJDTreatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980J Clin Oncol201129293907391321911721
   PubMed Web of Science ®Google Scholar
• VarkiALottenbergRGriffithRReinhardEThe syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survivalMedicine (Baltimore)19836263533716633248
   PubMed Web of Science ®Google Scholar
• MesaRANiblackJWadleighMThe burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patientsCancer20071091687617123268
   PubMed Web of Science ®Google Scholar
• JohanssonPMesaRScherberRAssociation between quality of life and clinical parameters in patients with myeloproliferative neoplasmsLeuk Lymphoma201253344144421883029
   PubMed Web of Science ®Google Scholar
• Abdel-WahabOILevineRLPrimary myelofibrosis: update on definition, pathogenesis, and treatmentAnnu Rev Med20096023324518947294
   PubMed Web of Science ®Google Scholar
• BarbuiTBarosiGBirgegardGPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetJ Clin Oncol201129676177021205761
   PubMed Web of Science ®Google Scholar
• MichielsJJClinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyondHematology200510Suppl 121522316188676
   PubMed Web of Science ®Google Scholar
• HasselbalchHIdiopathic myelofibrosis: a clinical study of 80 patientsAm J Hematol19903442913002195869
   PubMed Web of Science ®Google Scholar
• ScheinbergPYoungNSHow I treat acquired aplastic anemiaBlood201212061185119622517900
   PubMed Web of Science ®Google Scholar
• OuelletteDRThe impact of anemia in patients with respiratory failureChest20051285 Suppl 2576S582S16306056
   PubMed Web of Science ®Google Scholar
• PrenticeCRAcquired coagulation disordersClin Haematol19851424134423899441
   PubMedGoogle Scholar
• WolachBGavrieliRManorYLishnerMLeukocyte function in chronic myeloproliferative disordersBlood Cells Mol Dis19982445445519887281
   PubMed Web of Science ®Google Scholar
• PereiraABrugueraMCervantesFRozmanCLiver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two casesEur J Haematol19884043553613366226
   PubMed Web of Science ®Google Scholar
• O’ReillyRASplenomegaly at a United States County Hospital: diagnostic evaluation of 170 patientsAm J Med Sci199631241601658853064
   PubMed Web of Science ®Google Scholar
• Alvarez-LarránAAbraldesJGCervantesFPortal hypertension secondary to myelofibrosis: a study of three casesAm J Gastroenterol2005100102355235816181389
   PubMed Web of Science ®Google Scholar
• TefferiAMyelofibrosis with myeloid metaplasiaN Engl J Med2000342171255126510781623
   PubMed Web of Science ®Google Scholar
• AngerBRSeifriedEScheppachJHeimpelHBudd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseasesKlin Wochenschr198967168188252796252
   PubMedGoogle Scholar
• Bioulac-SagePRouxDQuintonALamouliatteHBalabaudCUltrastructure of sinusoids in patients with agnogenic myeloid metaplasiaJ Submicrosc Cytol19861848158213783800
   PubMedGoogle Scholar
• KochCALiCYMesaRATefferiANonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatmentMayo Clin Proc200378101223123314531481
   PubMed Web of Science ®Google Scholar
• NadrousHFKrowkaMJMcClureRFTefferiALimKGAgnogenic myeloid metaplasia with pleural extramedullary leukemic transformationLeuk Lymphoma200445481581815160962
   PubMed Web of Science ®Google Scholar
• AltomareGCapellaGLFrigerioESweet’s syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinateHaematologica199681154588900854
   PubMed Web of Science ®Google Scholar
• ChanACKwongYLLamCCGranulocytic sarcoma of megakaryoblastic differentiation complicating chronic idiopathic myelofibrosisHum Pathol19962744174208617486
   PubMed Web of Science ®Google Scholar
• FrohnaBJQuintDJGranulocytic sarcoma (chloroma) causing spinal cord compressionNeuroradiology19933575095118232876
   PubMed Web of Science ®Google Scholar
• AtallahEVerstovsekSEmerging drugs for myelofibrosisExpert Opin Emerg Drugs201217455557023186315
   PubMed Web of Science ®Google Scholar
• BenjaminiOJainPEstrovZKantarjianHMVerstovsekSTherapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegalyBlood2012120132768276923019204
   PubMed Web of Science ®Google Scholar
• SantosFPKantarjianHMJainNPhase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosisBlood201011561131113620008298
   PubMed Web of Science ®Google Scholar
• PardananiAGotlibJRJamiesonCSafety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosisJ Clin Oncol201129778979621220608
   PubMed Web of Science ®Google Scholar
• PardananiALabordeRRLashoTLSafety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia20132761322132723459451
   PubMed Web of Science ®Google Scholar
• VannucchiAMManagement of myelofibrosisHematology Am Soc Hematol Educ Program2011201122223022160038
   PubMed Web of Science ®Google Scholar
• MesaRAHow I treat symptomatic splenomegaly in patients with myelofibrosisBlood2009113225394540019332765
   PubMed Web of Science ®Google Scholar
• DaverNShastriAKadiaTModest activity of pomalidomide in patients with myelofibrosis and significant anemiaLeuk Res Epub7242013
   Web of Science ®Google Scholar
• Celgene CorporationPhase-3 double-blind, placebo-controlled study of pomalidomide in persons with myeloproliferative-neoplasm-associated myelofibrosis and RBC-transfusion-dependence myelofibrosis and RBC-transfusion-dependence (RESUME)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2010 [updated November 13, 2012]. Available from: http://clinicaltrials.gov/show/NCT01178281. NLM identifier: NCT01178281Accessed September 9, 2013
   Google Scholar
• Celgene CorporationCelgene reports first quarter 2013 operating and financial results [web page on the Internet]Summit, NJCelgene Corporation nd. Available from: http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1811033&highlight=myelofibrosisAccessed August 19, 2013
   Google Scholar
• JAKAVI® the first medication to receive health canada approval to treat patients with myelofibrosis [press release]CNW Group201275 Available from: http://www.newswire.ca/en/story/1003655/-pr-jakavi-the-first-medication-to-receive-health-canada-approval-to-treat-patients-with-myelofibrosisAccessed July 17, 2013
   Google Scholar
• NovartisAGNovartis drug JAKAVI® first medication to receive European Commission approval to treat patients with myelofibrosis [media release]BaselNovartis AG2012828 Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1636508.shtmlAccessed July 17, 2013
   Google Scholar
• Incyte CorporationCOntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2009 [updated May 13, 2013]. Available from: http://clinicaltrials.gov/show/NCT00952289. NLM identifier: NCT00952289Accessed September 9, 2013
   Google Scholar
• Novartis PharmaceuticalsCOntrolled MyeloFibrosis study with ORal Janus-associated kinase (JAK) inhibitor Treatment-II: The COMFORT-II TrialClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2009 [updated March 12, 2013]. Available from: http://clinicaltrials.gov/show/NCT00934544. NLM identifier: NCT00934544Accessed September 9, 2013
   Google Scholar
• Incyte CorporationOpen label ruxolitinib (INCB018424) in patients with myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosisClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2007 [updated October 9, 2012]. Available from: http://clinicaltrials.gov/show/NCT00509899. NLM identifier: NCT00509899Accessed September 9, 2013
   Google Scholar
• KvasnickaHMThieleJBueso-RamosCEExploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosisJ Clin Oncol201331Suppl Abstract 7030
   Google Scholar
• VaddiKSarlisNJGuptaVRuxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosisExpert Opin Pharmacother201213162397240723051187
   PubMed Web of Science ®Google Scholar